JP6110861B2 - ワクチン療法 - Google Patents

ワクチン療法 Download PDF

Info

Publication number
JP6110861B2
JP6110861B2 JP2014532040A JP2014532040A JP6110861B2 JP 6110861 B2 JP6110861 B2 JP 6110861B2 JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014532040 A JP2014532040 A JP 2014532040A JP 6110861 B2 JP6110861 B2 JP 6110861B2
Authority
JP
Japan
Prior art keywords
memory
subject
syndrome
aci
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014532040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531455A (ja
JP2014531455A5 (cg-RX-API-DMAC7.html
Inventor
アンドリア フェイファー
アンドリア フェイファー
アンドレアス ムース
アンドレアス ムース
リメ マダニ
リメ マダニ
パーベル ワシーリエヴィチ ベリチェンコ
パーベル ワシーリエヴィチ ベリチェンコ
ウィリアム チャールズ モブリー
ウィリアム チャールズ モブリー
Original Assignee
エーシー イミューン ソシエテ アノニム
エーシー イミューン ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーシー イミューン ソシエテ アノニム, エーシー イミューン ソシエテ アノニム filed Critical エーシー イミューン ソシエテ アノニム
Publication of JP2014531455A publication Critical patent/JP2014531455A/ja
Publication of JP2014531455A5 publication Critical patent/JP2014531455A5/ja
Application granted granted Critical
Publication of JP6110861B2 publication Critical patent/JP6110861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014532040A 2011-09-23 2012-09-21 ワクチン療法 Active JP6110861B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (3)

Publication Number Publication Date
JP2014531455A JP2014531455A (ja) 2014-11-27
JP2014531455A5 JP2014531455A5 (cg-RX-API-DMAC7.html) 2015-11-12
JP6110861B2 true JP6110861B2 (ja) 2017-04-05

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014532040A Active JP6110861B2 (ja) 2011-09-23 2012-09-21 ワクチン療法

Country Status (23)

Country Link
US (2) US20140314837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2758071B1 (cg-RX-API-DMAC7.html)
JP (1) JP6110861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160099732A (cg-RX-API-DMAC7.html)
CN (2) CN104039346A (cg-RX-API-DMAC7.html)
AU (1) AU2012312126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811188C (cg-RX-API-DMAC7.html)
DK (1) DK2758071T3 (cg-RX-API-DMAC7.html)
EA (1) EA032494B1 (cg-RX-API-DMAC7.html)
ES (1) ES2712951T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041277T2 (cg-RX-API-DMAC7.html)
IL (1) IL231564A0 (cg-RX-API-DMAC7.html)
MX (1) MX350928B (cg-RX-API-DMAC7.html)
MY (1) MY169574A (cg-RX-API-DMAC7.html)
PH (1) PH12014500657A1 (cg-RX-API-DMAC7.html)
PL (1) PL2758071T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758071T (cg-RX-API-DMAC7.html)
SG (1) SG11201400795UA (cg-RX-API-DMAC7.html)
SI (1) SI2758071T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901846T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013044147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402071B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Also Published As

Publication number Publication date
EP2758071A1 (en) 2014-07-30
EA201400376A1 (ru) 2014-09-30
US20140314837A1 (en) 2014-10-23
EA032494B1 (ru) 2019-06-28
JP2014531455A (ja) 2014-11-27
WO2013044147A1 (en) 2013-03-28
HUE041277T2 (hu) 2019-05-28
AU2012312126A1 (en) 2014-03-27
PT2758071T (pt) 2019-01-11
CN109847058A (zh) 2019-06-07
ES2712951T3 (es) 2019-05-16
PH12014500657A1 (en) 2014-05-05
IL231564A0 (en) 2014-04-30
AU2012312126B2 (en) 2016-11-10
PL2758071T3 (pl) 2019-08-30
CA2811188A1 (en) 2013-03-23
MY169574A (en) 2019-04-22
DK2758071T3 (en) 2019-02-18
MX2014003325A (es) 2014-05-21
KR20160005380A (ko) 2016-01-15
NZ622653A (en) 2015-12-24
CA2811188C (en) 2020-04-28
SG11201400795UA (en) 2014-10-30
ZA201402071B (en) 2017-08-30
BR112014006871A2 (pt) 2017-04-04
TR201901846T4 (tr) 2019-03-21
SI2758071T1 (sl) 2019-01-31
US20240270829A1 (en) 2024-08-15
KR102129220B1 (ko) 2020-07-02
MX350928B (es) 2017-09-26
KR20190035948A (ko) 2019-04-03
CN104039346A (zh) 2014-09-10
KR20160099732A (ko) 2016-08-22
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US20240270829A1 (en) Vaccine Therapy
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
AU2008267037B2 (en) Monoclonal anti beta amyloid antibody
US9585956B2 (en) Polynucleotides encoding anti-amyloid beta monoclonal antibodies
CN101883790B (zh) 抗淀粉样蛋白β抗体在眼病中的用途
US9146244B2 (en) Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
JP2011251964A (ja) 超分子コンストラクトを含む方法および組成物
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome
HK1197732A (en) Vaccine therapy
HK1197732B (en) Vaccine therapy

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170310

R150 Certificate of patent or registration of utility model

Ref document number: 6110861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250